ライフサイエンスコーパス: iothalamate

1 nds have a higher urine recovery compared to iothalamate.

2 nd simultaneous GFR measurements done with I-iothalamate.

3 ing urinary clearance of iodine 125 ((125)I) iothalamate.

4 ed serum creatinine and urinary clearance of iothalamate.

5 te was measured as urinary clearance of 125I-iothalamate.

6 ), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.

7 nds exhibit a plasma clearance equivalent to iothalamate (a commonly considered gold standard GFR age

8 espectively, in subjects who received (125)I-iothalamate and -33.2, -36.5, 6.0, and -15.0 for MDRD 1,

9 FRs and two eGFRs determined concurrently by iothalamate and creatinine (eGFRcr) or cystatin C, respe

10 ultaneously using a continuous infusion of I-iothalamate and external radioactivity measurement after

11 ate and renal plasma flow were measured with iothalamate and para-aminohippurate, respectively.

12 on markers and focus on urinary clearance of iothalamate and plasma clearance of iohexol compared wit

13 All donors had glomerular filtration rate (I-iothalamate) and effective renal plasma flow (I-hippuran

14 ney with the use of contrast material and an iothalamate-based measurement of the GFR during donor ev

15 al were similar for the serum creatinine and iothalamate-based measurements.

16 reatinine < or = 1.3 mg/dl and/or an initial iothalamate clearance > or = to 60 ml/min per 1.73 m(2)

17 All 20 participants with negative trends in iothalamate clearance (declining renal function) also ha

18 Renal function was evaluated on the basis of iothalamate clearance (GFR) and urinary protein and micr

19 ypertension was associated with a decline in iothalamate clearance (odds ratio [OR] 5.8; 95% confiden

20 at baseline was associated with a decline in iothalamate clearance (OR 2.4; 95% CI 1.5 to 3.7), eGFR

21 imates of GFR compared poorly with trends in iothalamate clearance (Spearman r < 0.35).

22 yr of follow-up, and yearly measurements of iothalamate clearance and serum cystatin C.

23 In paired comparisons of 100/cystatin C with iothalamate clearance at each examination, the two measu

24 GFR was measured by corrected iothalamate clearance at the time of transplant evaluati

25 Iothalamate clearance decreased in the first year in 96%

26 GFR was measured by nonradiolabeled iothalamate clearance determined by high-performance liq

27 s used to model GFR measured by using (125)I-iothalamate clearance from the significant variables.

28 total kidney volume, total cyst volume, and iothalamate clearance in patients with ADPKD.

29 Iothalamate clearance showed 18.5% improvement at 1 year

30 e-based GFR and GFR measured by using (125)I-iothalamate clearance was +0.42.

31 important, the trends in 100/cystatin C and iothalamate clearance were strongly correlated (Spearman

32 (para-aminohippuric acid clearance) and GFR (iothalamate clearance) over 8 to 24 hours.

33 l/min per 1.73 m2 at baseline (based on cold iothalamate clearance), 4 yr of follow-up, and yearly me

34 he effects of nesiritide on GFR (measured by iothalamate clearance), renal plasma flow (measured by p

35 his can be determined by measured GFR (e.g., iothalamate clearance), serum creatinine (SCr)-based GFR

36 on slopes had a mean residual SD of 10.7% by iothalamate clearance, 8.2% by MDRD equation, 7.7% by Co

37 Iothalamate clearance, SCr, and creatinine clearance wer

38 me, expressed as annual percentage change in iothalamate clearance, was determined.

39 blood oxygen level-dependent MRI and GFR by iothalamate clearance.

40 ultidetector computed tomography, and GFR by iothalamate clearance.

41 correlated with GFR measured by using (125)I-iothalamate clearance.

42 cans instead of measuring it by using (125)I-iothalamate clearance.

43 iffer for baseline characteristics or 1-year iothalamate clearance.

44 The GFR was measured in LT recipients by iothalamate clearance.

45 tal kidney volume and total cyst volume with iothalamate clearance.

46 tion as measured by GFR, assessed by (125) I-iothalamate clearance.

47 (125)I-iothalamate clearances and CVD evaluations including a 1

48 s were compared with renal clearance of 125I-iothalamate GFR (GFR1) in 193 hypertensive (diastolic bl

49 t-Gault (CG) formula as compared with (125)I-iothalamate GFR (iGFR) was analyzed in 423 donors.

50 ) equations as compared with measured (125)I-iothalamate GFR (iGFR) was analyzed in patients with chr

51 Unadjusted donor (125)I-iothalamate GFR (iGFR), donor age more than 45 years, do

52 n C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with iothalamate GFR (iGFR), including changes in each over t

53 nth postuninephrectomy values of GFR using I-iothalamate GFR (iGFR), modification of diet in renal di

54 h the relationships of the same factors with iothalamate GFR (iGFR)-based outcomes in the African Ame

55 stimates of GFR obtained using creatinine or iothalamate GFR (iGFR).

56 ndex (BMI) of 24.9 kg/m(2) and a mean (125)I-iothalamate GFR of 109 ml/min per 1.73 m(2).

57 /min per 1.73 m(2) and overestimated it when iothalamate GFR was >130 ml/min per 1.73 m(2).

58 s strong as or perhaps stronger than that of iothalamate GFR with these outcomes in stage 3 or 4 CKD.

59 ocals of these filtration markers and (125)I iothalamate GFR, expressed per SD, with kidney failure a

60 The MDRD substantially underestimated iothalamate GFR, whereas the Cockcroft Gault formula und

61 uracy was assessed by the difference of 125I-iothalamate GFR-estimated GFR (delta GFR), and precision

62 he formula's estimates were within +/-10% of iothalamate GFR.

63 r filtration rate measured by the iodine-125 iothalamate (Glofil) test and renal biopsy findings.

64 ; 2) lower fasting glucose levels; 3) higher iothalamate glomerular filtration rate (52+/-19 vs. 59+/

65 ABPM]), clinical, and renal characteristics (iothalamate glomerular filtration rate [GFR], urine prot

66 Median (range) iothalamate glomerular filtration rate and 24-hr urinary

67 Graft function was assessed using iothalamate glomerular filtration rate at 1, 4, and 12 m

68 ear after posttransplant, the patient has an iothalamate glomerular filtration rate of 58 ml/min.

69 death-censored graft loss or two consecutive iothalamate glomerular filtration rates less than 50 mL/

70 .1 for CG, and 28.6 for CG-GFR in the (125)I-iothalamate group and was 31.1 for MDRD 1, 38.2 for MDRD

71 filtration rate (GFR) using a marker such as iothalamate (iGFR) is superior to equation-estimated GFR

72 ainst GFR measured by the renal clearance of iothalamate in 1286 individuals with type 1 diabetes fro

73 s also had clearly positive slopes of (125)I-iothalamate-measured GFR during the trial phase.

74 In conclusion, iothalamate measurement of GFR is not consistently super

75 Ioversol 240 and iothalamate meglumine 43% were separately injected throu

76 60% iodinated contrast material (iohexol or iothalamate meglumine) was injected at either 2 mL/sec (

77 of 117 healthy individuals underwent (125)I-iothalamate or (99m)Tc-diethylenetriamine-pentaacetic ac

78 mpared it to GFR measured by nonradiolabeled iothalamate plasma clearance (mGFR) in 72 subjects with

79 A total of 586 iothalamate results were obtained in 401 patients after

80 0.14 for MDRD in those who underwent (125)I-iothalamate studies and 0.18 for CG, 0.21 for CG-GFR, 0.